共 50 条
- [21] Lack of adherence to infliximab in inflammatory bowel disease patients contributes to loss of response in Crohn's diseaseJOURNAL OF CROHNS & COLITIS, 2021, 15 : S518 - S519Ferreiro Iglesias, R.Gonzalez-Lopez, J.Calvino-Suarez, C.Mauriz-Barreiro, V.Baston-Rey, I.Cruz, R.Dominguez-Munoz, J. E.Barreiro-de Acosta, M.
- [22] A prospective cohort study to determine the relationship between serum infliximab concentration and efficacy in patients with luminal Crohn's diseaseALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2014, 39 (10) : 1126 - 1135Levesque, B. G.Greenberg, G. R.Zou, G.Sandborn, W. J.Singh, S.Hauenstein, S.Ohrmund, L.Wong, C. J.Stitt, L. W.Shackelton, L. M.King, D.Lockton, S.Ducharme, J.Feagan, B. G.
- [23] A distinct epigenetic profile distinguishes stenotic from non-inflamed fibroblasts in the ileal mucosa of Crohn's disease patientsPLOS ONE, 2018, 13 (12):Yim, Andrew Y. F. Lide Bruyn, Jessica R.Duijvis, Nicolette W.Sharp, CatrionaFerrero, Enricode Jonge, Wouter J.Wildenberg, Manon E.Mannens, Marcel M. A. M.Buskens, Christianne J.D'Haens, Geert R.Henneman, Peterte Velde, Anje A.
- [24] Development of a clinical model to predict secondary non-response of infliximab treatment in Crohn’s diseaseInternational Journal of Colorectal Disease, 2020, 35 : 2019 - 2026Lijun XuJun ShenQing Zheng
- [25] Development of a clinical model to predict secondary non-response of infliximab treatment in Crohn's diseaseINTERNATIONAL JOURNAL OF COLORECTAL DISEASE, 2020, 35 (11) : 2019 - 2026Xu, LijunShen, JunZheng, Qing
- [26] Predictors of Sustained Response to Infliximab in Patients With Crohn's Disease: A Single Cohort StudyGASTROENTEROLOGY, 2011, 140 (05) : S593 - S593Duricova, DanaMalickova, KarinBortlik, MartinMachkova, NadezdaKomarek, ViktorBouzkova, EvaLukas, Milan
- [27] Certolizumab Pegol Effectiveness in Crohn's Disease Patients with Secondary Failure to Infliximab Is Independent of Infliximab Dosing: Results from the WELCOME StudyGASTROENTEROLOGY, 2009, 136 (05) : A181 - A181Abreu, Maria T.Vermeire, SeverineRutgeerts, Paul J.Ullman, Thomas A.Wolf, Douglas C.Sandborn, William J.
- [28] Doubling the infliximab dose versus halving the infusion intervals in Crohn's disease patients with loss of responseINFLAMMATORY BOWEL DISEASES, 2012, 18 (11) : 2026 - 2033Katz, LiorGisbert, Javier P.Manoogian, BethLin, KirkSteenholdt, CasperMantzaris, Gerassimos J.Atreja, AshishRon, YuliaSwaminath, ArunShah, SomalHart, AilsaLakatos, Peter LaszloEllul, PierreIsraeli, EranSvendsen, Mads Naundrupvan der Woude, C. JannekeKatsanos, Konstantinos H.Yun, LauraTsianos, Epameinondas V.Nathan, TorbenAbreu, MariaDotan, IrisLashner, BretBrynskov', JornTerdiman, Jonathan P.Higgins, Peter D. R.Chaparro, MariaBen-Horin, Shomron
- [29] Identifying Patients at High Risk of Loss of Response to Infliximab Maintenance Therapy in Paediatric Crohn's DiseaseJOURNAL OF CROHNS & COLITIS, 2016, 10 (07): : 795 - 804Dupont-Lucas, ClaireSternszus, RobertEzri, JessicaLeibovitch, SamanthaGervais, FranceAmre, DevendraDeslandres, Colette
- [30] Therapeutic gain of continued, long-term infliximab therapy in Crohn's disease patients with response but non-remission after one year of infliximab therapyJOURNAL OF CROHNS & COLITIS, 2018, 12 : S487 - S488Buhl, S.Borghede, M. K.Brynskov, J.Steenholdt, C.Rasmussen, M.Ainsworth, M. A.